SCHEMBL2192152

SCHEMBL2192152

IN(I)C1CCCC1.[Pt]=c1[nH]c(Cc2ccccc2)nn1Cc1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.38
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 2/20 0.38
MAPT P10636 2/20 0.38
MEN1 O00255 1/20 0.38
TSHR P16473 1/20 0.38
KMT2A Q03164 1/20 0.38
HTT P42858 1/20 0.36
ALPL P05186 1/20 0.35
PDE9A O76083 1/20 0.35
PDE1C Q14123 1/20 0.35
ADORA1 P30542 7/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GRIN2B Q13224 1/20 0.33
MAPK1 P28482 1/20 0.33
ADORA3 P0DMS8 2/20 0.33
ADORA2A P29274 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2192353 0.99 ALDH1A1 (0.37) HSD17B10ALDH1A1KDM4EMAPTMEN1
SCHEMBL2196581 0.99 HSD17B10 (0.36) HSD17B10ALDH1A1KDM4EMAPTMEN1
SCHEMBL2195699 0.96 HSD17B10 (0.35) HSD17B10ALDH1A1KDM4EMAPTMEN1
SCHEMBL2195540 0.84 PDE5A (0.38) HSD17B10ALDH1A1KDM4EMAPTMEN1
SCHEMBL2196306 0.83 PDE5A (0.37) HSD17B10ALDH1A1MEN1KMT2AALPL
SCHEMBL2193923 0.83 PDE5A (0.38) ALPLPDE9APDE1C
SCHEMBL2194665 0.83 KDM4E (0.38) HSD17B10ALDH1A1KDM4EMEN1TSHR
SCHEMBL2196177 0.82 HSD17B10 (0.32) HSD17B10ALDH1A1KDM4EMAPTMEN1
SCHEMBL2193128 0.81 PDE5A (0.36) ALPLPDE9APDE1C
SCHEMBL2195682 0.78 SMN1; SMN2 (0.39) HSD17B10ALDH1A1KDM4EMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 HSD17B10 1394/4885ALDH1A1 1989/4885KDM4E 4803/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 HSD17B10 1394/4885ALDH1A1 1989/4885KDM4E 4803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.